Adrenal Disorders Therapeutics
1. Crenessity patent expiration
Treatment: Adjunctive treatment of classic congenital adrenal hyperplasia (cah)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12128033 | NEUROCRINE | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine |
Jun, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905690 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11311544 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11730739 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2029 |
| Orphan Drug Exclusivity(ODE-503) | Dec 13, 2031 |
Drugs and Companies using CRINECERFONT ingredient
NCE-1 date: 13 December, 2028
Market Authorisation Date: 13 December, 2024
Dosage: CAPSULE; SOLUTION
More Information on Dosage
CRENESSITY family patents
2. Isturisa patent expiration
Treatment: Cushing's disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(7 months from now) | |
| US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(5 years from now) | |
| US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(9 years from now) | |
| US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(5 years from now) | |
| US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Dosage: TABLET
More Information on Dosage
ISTURISA family patents